Vident International Equity Strategy ETF

Jazz Pharma to Hold Investor Webcast on Zanidatamab Phase 3 Trial Results

Jazz Pharmaceuticals Reports Positive Clinical Updates for Epidiolex and Ziihera

Jazz Pharmaceuticals' VP and CAO Patricia Carr Sells Shares

Jazz Pharmaceuticals' Senior Vice President Disposes of Common Stock

Jazz Pharmaceuticals Displays Xywav® Efficacy Data for Treating Narcolepsy

Schroder Investment Management Group Increased Holdings in Jazz Pharmaceuticals by 90.1%

Jazz Pharma to Present New Treatment Data on Epidiolex® at AAN Annual Meeting

Jazz Pharmaceuticals Director O'Keefe Sold 603 Shares of Company Stock

Jazz Pharmaceuticals to Present Ziihera® Phase 3 Trial Results at ASCO GI 2026

Bruce C Cozadd sold 77,500 shares of Jazz Pharmaceuticals

MomoTech Reports Strong Q3 Earnings, Adjusted Net Profit Up 167%

Jazz Pharmaceuticals Director Heather Ann McSharry Sells Shares

UBS Analyst Maintains Hold Rating on Jazz Pharma

Mobvista Reports Q3 Net Loss of $54.533 Million, Revenue Up 27.6%

Mobvista Reports Strong Q3 2025 Financial Performance

MOBVISTA released FY2025 Q3 earnings on November 21 After-Market (BJT), actual revenue HKD 4.137 B, actual EPS HKD -0.2778

MOBVISTA released FY2025 9 Months earnings on November 21 After-Market (BJT), actual revenue HKD 11.47 B, actual EPS HKD -0.1141

Mintegral Reports Q3 Revenue Growth but Turns Loss

Jazz Pharmaceuticals Director Sells Ordinary Shares

Jazz Pharmaceuticals VP Exercises Options and Sells Shares

Luminar Tech

Novabay Pharmac

Mint Incorporation

Autozi Internet Tech Global

GD Culture

Impact BioMedical

Tradr 2X Long FLY Daily ETF

Leverage Shares 2X Long CRWV Daily ETF

T-REX 2X Long CRWV Daily Target ETF

JAZZ

Jazz Pharmaceuticals announced its participation in upcoming investor events, including a webcast on January 9, 2026, to review Phase 3 trial results, and a presentation at the J.P. Morgan Healthcare Conference on January 13, 2026. The company will provide updates on its strategy and business. Webcasts will be available on their website.

StockTitan

Jazz Pharma

Jazz Pharmaceuticals to Participate in Upcoming Investor Events | JAZZ Stock News

Jazz Pharmaceuticals (JAZZ) has gained investor interest following positive clinical updates for Epidiolex and Ziihera. The stock price is now $167.50, with a 30-day return of 18.74% and a 1-year return of 36.13%. Despite this, JAZZ trades nearly 30% below consensus targets, with a fair value estimate of $208.50. Analysts are bullish on Ziihera's potential in HER2 positive GEA. However, risks include patent cliffs and competition in HER2 oncology. Investors are encouraged to explore other healthcare stocks and use tools like Simply Wall St Screener for further research.

Simplywall

Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest

02643

02650

09989

02268

02076

03360

02858

00565

01860

02096

CAOCAO INC(02643) fell 11.11%, with a trading turnover 182.4 Million HKD, and a year-to-date fell 1.2%. ZHIDA TECH(02650) fell 7.89%, with a trading turnover 8.7 Million HKD, and a year-to-date rose 224.6%. HEPALINK(09989) fell 7.21%, with a trading turnover 22.3 Million HKD, and a year-to-date rose 39.6%.

Top Gainers & Losers

CAOCAO INC

ZHIDA TECH

HEPALINK

WUXI XDC

BOSS ZHIPIN-W

FE HORIZON

YIXIN

ART GROUP HOLD

MOBVISTA

SIMCERE PHARMA

Top 10 HK Stock Losers (12.12)

Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing

marketscreener

Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing

Mary Elizabeth Henderson, SVP of Technical Operations at Jazz Pharmaceuticals, reported the sale of common shares. The filing is available via EDGAR, the SEC's system. This AI-generated brief is for informational purposes only and not financial advice. Jazz Pharmaceuticals is responsible for the original content.

Reuters

Jazz Pharmaceuticals SVP Technical Operations Mary Elizabeth Henderson Reports Sale of Common Shares

08349

Overview of the Hong Kong Stock Market In the past hour, the Hong Kong stock market has shown a significant phenomenon of sector rotation. Technology stocks and thematic stocks have performed particularly well, with capital flows seemingly favoring short-term opportunities, and market sentiment appearing slightly active. Small-cap stocks have experienced large fluctuations, indicating investors' preference for high-risk, high-return investments. The overall pace is fast, with funds quickly switching between different sectors, demonstrating the flexibility of market participants. The stock with the largest abnormal movement in the past hour is Mobvista, which has attracted attention with a 15.24% increase. The rapid inflow of funds has driven up the stock price, reflecting the market's optimistic expectations for its future development. The active short-term funds have intensified stock price fluctuations, leading to heightened investor sentiment. Strong stocks: 1. Mobvista: up 15.24%, with significant capital inflow and an optimistic market outlook. Pressured stocks: 1. GUIXIN GROUP: down 20.51%, with the market holding a cautious attitude towards its short-term performance and significant capital outflow

HK Stock Movers Tracker

GUIXIN GROUP

Hong Kong Stock Movement Quick Report: MOBVISTA rises over 15%, GUIXIN GROUP falls 20%, market volatility intensifies

MOBVISTA rose 15.24%; China Literature Group fell 3.12%, with a transaction volume of HKD 243 million; Qutoutiao Group fell 14.13%, with a transaction volume of HKD 116 million; Jihong Co., Ltd. fell 0.61%, with a transaction volume of HKD 34.19 million; Xinhua Wenhui fell 0.87%, with a market value of HKD 12.6 billion

Hong Kong Stock Movement: MOBVISTA rises 15.24%, with active trading and significant capital inflow, showing notable volatility

MOBVISTA rose 10.14%; China Literature Group fell 1.98%, with a transaction volume of HKD 166 million; Qutoutiao fell 12.56%, with a transaction volume of HKD 80.47 million; Jihong Co., Ltd. fell 1.14%, with a transaction volume of HKD 19.15 million; Xinhua Wenhui fell 0.87%, with a market value of HKD 12.6 billion

Hong Kong Stock Movement: MOBVISTA rises 10.14%, active trading attracts market attention, what secrets lie behind the volatility?

Jazz Pharmaceuticals has filed an initial statement of beneficial ownership (Form 3) with the U.S. SEC, listing Ted W. Love as a director. The filing is available via EDGAR. This news brief was created by Public Technologies using AI and is for informational purposes only.

Jazz Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Ted W. Love

VP Henderson of Jazz Pharmaceuticals filed a Form 144 with the SEC to sell 2,238 restricted shares on December 9, 2025. The sale will be managed by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing. The Washington Service offers insider trading analysis and data services.

VP Henderson Files To Sell 2,238 Of Jazz Pharmaceuticals Plc [JAZZ]